Your browser doesn't support javascript.
loading
Mechanistic Modeling of the Drug-Drug Interaction Between Efavirenz and Dolutegravir: Is This Interaction Clinically Relevant When Switching From Efavirenz to Dolutegravir During Pregnancy?
Dallmann, André; van den Anker, John; Ahmadzia, Homa K; Rakhmanina, Natella.
Affiliation
  • Dallmann A; Pharmacometrics/Modeling & Simulation, Research & Development, Pharmaceuticals, Bayer AG, Germany.
  • van den Anker J; Division of Clinical Pharmacology, Children's National Hospital, Washington, District of Columbia, USA.
  • Ahmadzia HK; Paediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, University of Basel, Basel, Switzerland.
  • Rakhmanina N; Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA.
J Clin Pharmacol ; 63 Suppl 1: S81-S95, 2023 06.
Article in En | MEDLINE | ID: mdl-37317489
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV Infections Type of study: Guideline / Prognostic_studies Limits: Female / Humans / Pregnancy Language: En Journal: J Clin Pharmacol Year: 2023 Document type: Article Affiliation country: Germany Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV Infections Type of study: Guideline / Prognostic_studies Limits: Female / Humans / Pregnancy Language: En Journal: J Clin Pharmacol Year: 2023 Document type: Article Affiliation country: Germany Country of publication: United kingdom